Exact Sciences Announces Study Showing Cologuard Plus™ Delivers Most Life-Years Gained With Fewer Colonoscopies, According to Journal of the National Cancer Institute
Reuters
Oct 07
Exact Sciences Announces Study Showing Cologuard Plus™ Delivers Most Life-Years Gained With Fewer Colonoscopies, According to Journal of the National Cancer Institute
Exact Sciences Corporation announced the publication of a new modeling study in the Journal of the National Cancer Institute evaluating the benefit-to-burden ratios of established and emerging colorectal cancer screening strategies. The study found that Cologuard Plus™, a next-generation multitarget stool DNA (mt-sDNA) test, was the only noninvasive screening option shown to be efficient at guideline-recommended intervals and age ranges for average-risk adults starting at age 45. The analysis, based on the CRC-AIM microsimulation platform and methodologies adopted by the United States Preventive Services Task Force, incorporated updated clinical data and was sponsored by Exact Sciences. The results of the study have been published and are now available.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. EXACT Sciences Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 20251007788732) on October 07, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.